Editas Medicine Inc (EDIT) - Total Assets
Based on the latest financial reports, Editas Medicine Inc (EDIT) holds total assets worth $149.34 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Editas Medicine Inc for net asset value and shareholders' equity analysis.
Editas Medicine Inc - Total Assets Trend (2013–2025)
This chart illustrates how Editas Medicine Inc's total assets have evolved over time, based on quarterly financial data.
Editas Medicine Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Editas Medicine Inc's total assets of $149.34 Million consist of 87.9% current assets and 12.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 78.6% |
| Accounts Receivable | $15.18 Million | 8.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Editas Medicine Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EDIT market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Editas Medicine Inc's current assets represent 87.9% of total assets in 2025, an increase from 84.2% in 2013.
- Cash Position: Cash and equivalents constituted 78.6% of total assets in 2025, down from 81.1% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 8.1% of total assets.
Editas Medicine Inc Competitors by Total Assets
Key competitors of Editas Medicine Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.21 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Crispr Therapeutics AG
NASDAQ:CRSP
|
USA | $2.73 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Ascendis Pharma AS
F:A71
|
Germany | €2.00 Billion |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Editas Medicine Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.22 | 3.08 | 9.34 |
| Quick Ratio | 3.22 | 3.08 | 10.66 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $88.29 Million | $151.73 Million | $550.28 Million |
Editas Medicine Inc - Advanced Valuation Insights
This section examines the relationship between Editas Medicine Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 69.08 |
| Latest Market Cap to Assets Ratio | 1.45 |
| Asset Growth Rate (YoY) | -45.4% |
| Total Assets | $186.53 Million |
| Market Capitalization | $270.22 Million USD |
Valuation Analysis
Above Book Valuation: The market values Editas Medicine Inc's assets above their book value (1.45x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Editas Medicine Inc's assets decreased by 45.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Editas Medicine Inc (2013–2025)
The table below shows the annual total assets of Editas Medicine Inc from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $186.53 Million | -45.39% |
| 2024-12-31 | $341.59 Million | -31.57% |
| 2023-12-31 | $499.15 Million | -2.95% |
| 2022-12-31 | $514.32 Million | -24.08% |
| 2021-12-31 | $677.48 Million | +18.32% |
| 2020-12-31 | $572.60 Million | +12.52% |
| 2019-12-31 | $508.88 Million | +21.05% |
| 2018-12-31 | $420.39 Million | +12.63% |
| 2017-12-31 | $373.26 Million | +62.87% |
| 2016-12-31 | $229.18 Million | +53.44% |
| 2015-12-31 | $149.36 Million | +1125.49% |
| 2014-12-31 | $12.19 Million | +391.25% |
| 2013-12-31 | $2.48 Million | -- |
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The… Read more